Fire Capital Management LLC Makes New $577,000 Investment in Bristol Myers Squibb Company $BMY

Fire Capital Management LLC bought a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,020 shares of the biopharmaceutical company’s stock, valued at approximately $577,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. raised its position in Bristol Myers Squibb by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock valued at $10,719,376,000 after purchasing an additional 2,743,759 shares during the last quarter. State Street Corp increased its stake in shares of Bristol Myers Squibb by 1.4% during the fourth quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock valued at $5,285,065,000 after buying an additional 1,385,206 shares during the period. Geode Capital Management LLC raised its holdings in shares of Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after acquiring an additional 6,084,046 shares in the last quarter. Norges Bank purchased a new stake in Bristol Myers Squibb in the fourth quarter worth $1,947,272,000. Finally, AQR Capital Management LLC lifted its stake in Bristol Myers Squibb by 172.6% in the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after acquiring an additional 16,332,924 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Trading Down 1.2%

Shares of NYSE:BMY opened at $63.86 on Friday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.10. The company has a market cap of $130.45 billion, a P/E ratio of 14.07, a PEG ratio of 0.17 and a beta of 0.22. The stock’s fifty day moving average price is $59.56 and its 200-day moving average price is $58.97.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Sell-side analysts expect that Bristol Myers Squibb Company will post 6.96 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.9%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is presently 55.51%.

Analyst Ratings Changes

Several research firms have recently commented on BMY. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Truist Financial restated a “buy” rating and issued a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Jefferies Financial Group cut Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, August 5th. Raymond James Financial initiated coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “strong-buy” rating for the company. Finally, Bank of America reduced their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Moderate Buy” and an average price target of $66.06.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The U.S. FDA granted accelerated approval to ZENBEXUS, Bristol Myers Squibb’s first CELMoD therapy, in combination with daratumumab, hyaluronidase-fihj and dexamethasone for multiple myeloma patients as early as first relapse. The approval is strategically important because CELMoD drugs could help extend and rejuvenate the company’s important blood-cancer franchise. Bristol Myers wins milestone FDA approval of myeloma drug acquired from Celgene
• Positive Sentiment: Zacks Research raised its Bristol Myers Squibb EPS outlook for fiscal 2027 to $6.20 from $5.93. It also increased estimates for the fourth quarter of 2026, the first and second quarters of 2027, and the first two quarters of 2028, suggesting improved analyst expectations for earnings momentum.
• Positive Sentiment: The company expanded its kidney-disease pipeline with a Phase 1 study of golcadomide, providing another potential long-term growth opportunity beyond its established oncology products. Bristol-Myers Squibb expands kidney pipeline with new golcadomide renal study
• Neutral Sentiment: Rumors of a potential AstraZeneca-Bristol Myers Squibb merger have generated investor concern. Although a transaction could create a sizable oncology-focused pharmaceutical company, the strategic, financial and execution risks remain uncertain, and no deal was confirmed. Reported AstraZeneca-Bristol Myers Squibb megamerger
• Negative Sentiment: A federal appeals court revived a $6.7 billion lawsuit alleging Bristol Myers Squibb delayed approval of drugs acquired through Celgene, including Breyanzi. The case could create substantial financial liability and legal uncertainty. Lawsuit against Bristol Myers over delayed cancer drug is revived

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.